Stopping Clinical Trials in Inflammatory Bowel Disease During the COVID-19 Pandemic Is Not a Responsible Act.
J Crohns Colitis
; 14(12): 1765-1768, 2020 Dec 02.
Article
in English
| MEDLINE | ID: covidwho-614015
ABSTRACT
The intense competition for resources to combat COVID-19 has greatly reduced access to health care for patients with other diseases. After the disastrous overrun of hospitals through COVID-19 patients in some jurisdictions, availability of resources for 'elective' medical procedures, including care for the chronically ill, has been greatly reduced in many places as a pre-emptive measure before or during the blooming of infection clusters. Pharmaceutical companies have either stopped recruitment or even cancelled ongoing clinical trials in chronic diseases. Pre-emptive triage and its impact on medical ethics is discussed in the framework of care for inflammatory bowel disease.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Health Care Rationing
/
Inflammatory Bowel Diseases
/
Clinical Trials as Topic
/
Drug Development
/
COVID-19
/
Health Services Accessibility
/
Anti-Inflammatory Agents
Type of study:
Observational study
/
Prognostic study
/
Randomized controlled trials
Limits:
Humans
Language:
English
Journal:
J Crohns Colitis
Journal subject:
Gastroenterology
Year:
2020
Document Type:
Article
Affiliation country:
Ecco-jcc
Similar
MEDLINE
...
LILACS
LIS